{
    "nctId": "NCT06443645",
    "briefTitle": "Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B",
    "officialTitle": "Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis - SCARA-B",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Evaluate the expression of SGLT2",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient \\> 18 years old\n* Diagnosed with localized breast cancer\n* Indication for first-line surgery or anthracycline-based chemotherapy.\n\nExclusion Criteria:\n\n* History of chemotherapy or targeted therapy or immunotherapy administered before inclusion\n* Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2\n* Patient with known heart disease (ischemic, rhythmic, valvular, etc.)\n* Patient with a Glomerular filtration rate \\< 45 mL/min/1.73m\u00b2 according to the pre-therapeutic assessment\n* Patient with impaired liver function\n* Patient who is pregnant or breastfeeding\n* Patient with a second cancer undergoing treatment\n* Patient under guardianship or curatorship, protection of justice or deprived of liberty",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}